Latest Breaking News On - Deepakl bhatt - Page 2 : comparemela.com

New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups

New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesNew jerseyUnited arab emiratesUnited kingdomGreat britainMark marmurNabil abadirColl cardiolDeepakl bhattClin cardiolHead of global medical affairsAmerican heart associationExchange commissionJournal of the american college cardiologyAmarin corporationDrug administration

Viatris Hosts R&D Event Focusing on its Collaboration with Idorsia, Phase 3 Assets Selatogrel and Cenerimod and Key Elements of its Pipeline

/PRNewswire/ At a meeting with the investment community today, Viatris Inc. (NASDAQ: VTRS), a global healthcare company, will outline how it is continuing.

Andhra pradeshDoretta mistrasDeepakl bhattPhilippe martinScotta smithAnca askanaseRajiv malikLupus centerColumbia universityYork universityDrug administrationViatris incAcute myocardial infarctionSpecial protocol assessmentSystemic lupus erythematosusChief executive

Research Evaluating Benefits of VASCEPA/VAZKEPA (icosapent ethyl) to be Presented at the American College of Cardiology s (ACC) Annual Scientific Session & Expo Seite 1

25.03.2024 - - Subgroup Analyses from REDUCE-IT and Mechanistic Data on Icosapent Ethyl(IPE)/Eicosapentaenoic Acid (EPA) Featured at the Meeting - DUBLIN, Ireland and BRIDGEWATER, N.J., March 25, 2024 (GLOBE NEWSWIRE) - Amarin Corporation plc (NASDAQ:AMRN) . Seite 1

Michael millerElliota brintonNabil abadirDeepakl bhattHead of global medical affairs at amarinChief medical officerGlobal medical affairsAvailable aprilModerated poster theaterAmarin chartMarin kursMarin aktie

Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology s (ACC) Annual Scientific Session & Expo -March 25, 2024 at 08:00 am EDT

Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology s (ACC) Annual Scientific Session & Expo -March 25, 2024 at 08:00 am EDT
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United statesNew jerseyUnited arab emiratesBrady parkUnited kingdomGreat britainEhab bakbakMark marmurPeter libbyR preston masonSamuelcr sherrattElliota brintonMichael szarekAishwarya krishnarajDeepakl bhattNabil abadir

Viatris and Idorsia Enter Into Significant Global Research and Development Collaboration

Expands Viatris Portfolio of Innovative Assets by Immediately Adding Two Phase 3 Assets, Selatogrel and Cenerimod, Both With Blockbuster Revenue PotentialIncludes Future Optionality to Expand.

Andhra pradeshNew yorkUnited statesSouth koreaNew york universityColumbia universityScotta smithAnca askanaseJean paul clozelPhilippe martinDeepakl bhattIdorsia ltdLupus centerViatris incSwiss exchangePrnewswire viatris inc